New Drug Blocks COVID-19 Entry into the Host Cell

Entry of SARS-CoV2 into the host cell is facilitated by enzyme protease removes the spike proteins. Protease inhibitor drug aprotinin can help block this enzyme and hence prevent entry of coronavirus.

On the surface of the SARS-CoV2, spike proteins that help the virus to attach to proteins called as ACE2 (Angiotensin-converting enzyme-2) receptors are present.

Before the attachment process, the spike proteins have to be removed by enzymes called proteases which are secreted by the human cells.

Existing Treatment Helps Save the Lives of COVID-19 Patients
COVID-19 hospitalized patients could be saved by doctors by using an existing medical treatment at an earlier stage.

‘Entry of SARS-CoV2 into the host cell is facilitated by the enzyme protease which helps to remove spike proteins. Protease inhibitor drug aprotinin can block this enzyme and hence prevent entry of virus. Aerosol aprotinin is already approved in Russia for influenza treatment which has similar mechanism.’
Read More..

The international scientific team was led by Professor Jindrich Cinatl, Institute for Medical Virology at the University Hospital Frankfurt, Professor Martin Michaelis, and Dr Mark Wass (both University of Kent).

They demonstrated in cell culture experiments that a protease inhibitor drug called as aprotinin can block the replication of the coronavirus by preventing its entry into the host cells.

The drug was also seen to compensate for the SARS-CoV2-induced reduction of endogenous protease inhibitors in the already infected cells.

FDA Authorizes Monoclonal Antibodies for COVID-19 Treatment
US FDA issued an emergency use authorization for casirivimab and imdevimab for treatment of mild to moderate COVID-19.

Similar to coronavirus, the influenza virus also requires proteases for entry into the host cell, hence in Russia aprotinin aerosol is already approved for the treatment of influenza.

Professor Jindrich Cinatl said,“ Our findings show that aprotinin is effective against SARS-CoV2 in concentrations that can be achieved in patients. In aprotinin we have a drug candidate for the treatment of COVID-19 that is already approved for other indications and could readily be tested in patients."

Drugmaker AstraZeneca is Facing Tough Questions From Experts
After disclosing promising results from its COVID-19 vaccine trial earlier this week, drugmaker AstraZeneca is now facing tough questions from experts, especially after the company.

Source-Medindia

Ringing Sensation in the Ear (Tinnitus) Worsens During COVID-19 Pandemic
Patients with tinnitus have reported that during this pandemic their hearing condition is worsening. Many of them experienced tinnitus after the COVID-19 infection.